Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population

Future Oncol. 2024;20(20):1385-1392. doi: 10.1080/14796694.2024.2351352. Epub 2024 Jul 26.

Abstract

Aim: Assess the time-to-treatment discontinuation (TTD) and overall survival (OS) in a Swedish metastatic renal cell carcinoma (mRCC) nationwide cohort who received second-line axitinib.Methods: Retrospective analysis of 110 patients with mRCC treated with second-line axitinib in Sweden (2012-2019). Patients included in the study received axitinib after mainly first-line sunitinib or pazopanib.Results: The median (95% CI) TTD of patients who received second-line axitinib was 5.2 (3.7-6.1) months with 6 (5.5%) patients still receiving treatment at the time of analysis. Median (95% CI) OS was 12.2 (7.7-14.2) months.Conclusion: The results are consistent with previous findings in mRCC and add to the evidence demonstrating efficacy of second-line axitinib, after failure of a prior anti-angiogenic therapy in a real-world setting.Clinical Trial Registration: NCT04669366 (ClinicalTrials.gov).

Keywords: axitinib; metastatic renal cell carcinoma; real-world; second-line axitinib.

Plain language summary

[Box: see text].

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Axitinib* / administration & dosage
  • Axitinib* / therapeutic use
  • Carcinoma, Renal Cell* / drug therapy
  • Carcinoma, Renal Cell* / mortality
  • Carcinoma, Renal Cell* / pathology
  • Female
  • Humans
  • Indazoles / therapeutic use
  • Kidney Neoplasms* / drug therapy
  • Kidney Neoplasms* / mortality
  • Kidney Neoplasms* / pathology
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors* / therapeutic use
  • Pyrimidines
  • Retrospective Studies
  • Sulfonamides
  • Sweden / epidemiology
  • Time-to-Treatment / statistics & numerical data
  • Treatment Outcome

Substances

  • Axitinib
  • Indazoles
  • pazopanib
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Sulfonamides

Associated data

  • ClinicalTrials.gov/NCT04669366

Grants and funding